Disc Medicine, Inc. is facing a class action lawsuit after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This announcement caused the company's stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securities claims and preparing a class action to help investors recover losses without upfront fees. Investors who purchased Disc Medicine securities may be eligible to join the lawsuit for compensation.
Standard Chartered analyst Geoffrey Kendrick says recent selling pressure on Bitcoin and Strategy Inc. (MSTR) shares stems from market confusion over the company's shift from accumulating Bitcoin to using it as collateral for credit products like STR...
Donald Trump's recent financial disclosure revealed he owns $1.67 million worth of Micron Technology stock. This stake highlights his investment interest in the semiconductor sector, a key area in tech and global supply chains. The disclosure provide...
Ethereum's Market Value to Realized Value (MVRV) ratio dropped below 0.8, indicating it is trading under its realized value—a condition seen only during major market bottoms in past cycles. This suggests potential long-term accumulation despite no im...
Morgan Stanley Bitcoin Trust increased its Bitcoin holdings by nearly 1,000 BTC in two weeks, reaching 5,761 BTC worth about $370 million. This growth occurred despite Bitcoin's weak market conditions, reflecting sustained investor demand for the ban...
A social media post claims Anthropic could release a new AI model next week that outperforms OpenAI's GPT-5.6 Sol in intelligence and cost, though this is unconfirmed. Anthropic's current top model is Claude Fable 5, released globally after export co...
